<DOC>
	<DOCNO>NCT01974245</DOCNO>
	<brief_summary>Hypovitaminosis D highly prevalent among patient chronic kidney disease , especially undergoing dialysis . The loss protein dialysis solution seem contribute significantly reduce serum level vitamin D patient . As result disease dialysis procedure , high prevalence chronic inflammation high risk infection . There evidence population , vitamin D immunomodulatory effect stimulate production cathelicidin , antimicrobial peptide suppress production proinflammatory cytokine . Thus , study aim investigate effect cholecalciferol supplementation immunological marker patient hemodialysis peritoneal dialysis hypovitaminosis D . This randomized , double-blind , placebo-controlled trial patient vitamin D deficiency [ 25 ( OH ) D &lt; 20 ng / mL ] allocate intervention group ( cholecalciferol ) control ( placebo ) . Patients receive supplement 100,000 IU / week cholecalciferol period 12 week . Before intervention determine 25 ( OH ) D , cathelicidin , interleukin-6 ( IL-6 ) , tumor necrosis factor-α ( TNF-α ) C-reactive protein serum . In monocyte , evaluate cathelicidin , IL-6 TNF-α , 25 ( OH ) D receptor α 1-hydroxylase enzyme expression .</brief_summary>
	<brief_title>Supplementation With Cholecalciferol Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>25 ( OH ) &lt; 20 ng/ml Peritoneal dialysis hemodialysis &gt; 3 month Use vitamin D analogue , corticosteroid immunosuppressive Peritonitis previous month baseline Liver , neoplastic , infectious autoimmune disease positive HIV Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cholecalciferol</keyword>
	<keyword>Kidney disease</keyword>
</DOC>